Two Months On, U.S. DOJ Withdraws Motion Against Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Two months after filing a motion to enforce subpoenas against Indian drug maker Ranbaxy, the U.S. Department of Justice has withdrawn from taking further action. "The DOJ expressed its satisfaction with the documents submitted by Ranbaxy and Parexel Consulting," a source familiar with the issue informed PharmAsia News.